Related papers: CognitiveTwin: Robust Multi-Modal Digital Twins fo…
Cognitive decline is highly heterogeneous across individuals, which complicates prognosis, trial design, and treatment planning. We present the Personalized Cognitive Decline Assessment Digital Twin (PCD-DT), a multimodal and…
Alzheimer's Disease (AD) is a neurodegenerative disease that affects subjects in a broad range of severity and is assessed in clinical trials with multiple cognitive and functional instruments. As clinical trials in AD increasingly focus on…
Alzheimer's Disease (AD) is marked by significant inter-individual variability in its progression, complicating accurate prognosis and personalized care planning. This heterogeneity underscores the critical need for predictive models…
Alzheimer's disease (AD) is characterized by the progressive spread of pathology across brain networks, yet forecasting this cascade at the individual level remains challenging. We present a personalized graph-based dynamical model that…
Alzheimer's Disease (AD) is a complex neurodegenerative disorder marked by memory loss, executive dysfunction, and personality changes. Early diagnosis is challenging due to subtle symptoms and varied presentations, often leading to…
The ability to predict the future trajectory of a patient is a key step toward the development of therapeutics for complex diseases such as Alzheimer's disease (AD). However, most machine learning approaches developed for prediction of…
Alzheimer's Disease (AD) is an irreversible neurodegenerative disease characterized by progressive cognitive decline as its main symptom. In the research field of deep learning-assisted diagnosis of AD, traditional convolutional neural…
Alzheimers Disease (AD) is a progressive neurodegenerative disorder that poses significant challenges in its early diagnosis, often leading to delayed treatment and poorer outcomes for patients. Traditional diagnostic methods, typically…
INTRODUCTION: Heterogeneity in the progression of Alzheimer's disease makes it challenging to predict the rate of cognitive and functional decline for individual patients. Tools for short-term prediction could help enrich clinical trial…
Fusing structural-functional images of the brain has shown great potential to analyze the deterioration of Alzheimer's disease (AD). However, it is a big challenge to effectively fuse the correlated and complementary information from…
In order to find effective treatments for Alzheimer's disease (AD), we need to identify subjects at risk of AD as early as possible. To this end, recently developed disease progression models can be used to perform early diagnosis, as well…
Accurate diagnosis of Alzheimer's Disease (AD) entails clinical evaluation of multiple cognition metrics and biomarkers. Metrics such as the Alzheimer's Disease Assessment Scale - Cognitive test (ADAS-cog) comprise multiple subscores that…
Disease modifying therapies for Alzheimer's disease demand precise timing decisions, yet current predictive models require longitudinal observations and provide no uncertainty quantification, rendering them impractical at the critical first…
For effective treatment of Alzheimer disease (AD), it is important to identify subjects who are most likely to exhibit rapid cognitive decline. Herein, we developed a novel framework based on a deep convolutional neural network which can…
Alzheimer's disease (AD) is known as one of the major causes of dementia and is characterized by slow progression over several years, with no treatments or available medicines. In this regard, there have been efforts to identify the risk of…
Early and accurate diagnosis of Alzheimer Disease is critical for effective clinical intervention, particularly in distinguishing it from Mild Cognitive Impairment, a prodromal stage marked by subtle structural changes. In this study, we…
Alzheimer's disease (AD) is the most common neurodegenerative disease in older people. Despite considerable efforts to find a cure for AD, there is a 99.6% failure rate of clinical trials for AD drugs, likely because AD patients cannot…
Alzheimer's disease (AD) is a complex, multifactorial neurodegenerative disorder with substantial heterogeneity in progression and treatment response. Despite recent therapeutic advances, predictive models capable of accurately forecasting…
Robust forecasting of the future anatomical changes inflicted by an ongoing disease is an extremely challenging task that is out of grasp even for experienced healthcare professionals. Such a capability, however, is of great importance…
The aging population of the U.S. drives the prevalence of Alzheimer's disease. Brookmeyer et al. forecasts approximately 15 million Americans will have either clinical AD or mild cognitive impairment by 2060. In response to this urgent…